Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Single Treatment With FT1050 of an Ex-vivo Modultated Umbilical Cord Blood Unit
A Phase I/II Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Status: Enrolling
Updated:  2/3/2012
Ohio State Univeristy Comprehensive Cancer Center
mi
from
Columbus, OH
Single Treatment With FT1050 of an Ex-vivo Modultated Umbilical Cord Blood Unit
A Phase I/II Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies
Status: Enrolling
Updated: 2/3/2012
Ohio State Univeristy Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide
(RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell NHL
Status: Enrolling
Updated:  2/7/2012
Unviersity of California Medical Center
mi
from
San Francisco, CA
Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide
(RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell NHL
Status: Enrolling
Updated: 2/7/2012
Unviersity of California Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
Infusion of Genetically Modified T Cells: A Pilot Study of Tracking and Toxicity
Status: Enrolling
Updated:  3/2/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
Infusion of Genetically Modified T Cells: A Pilot Study of Tracking and Toxicity
Status: Enrolling
Updated: 3/2/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  3/6/2012
Rady Children's Hospital and Health Center
mi
from
San Diego, CA
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 3/6/2012
Rady Children's Hospital and Health Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  3/6/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 3/6/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Longitudinal Survey Analysis in Lymphoma Survivors
Coping With Lymphoma to Enhance Adjustment and Reduce Stress in Lymphoma Survivors
Status: Enrolling
Updated:  3/7/2012
New York Presbyterian/Weill Cornell Center for Lymphoma and Myeloma
mi
from
New York, NY
Longitudinal Survey Analysis in Lymphoma Survivors
Coping With Lymphoma to Enhance Adjustment and Reduce Stress in Lymphoma Survivors
Status: Enrolling
Updated: 3/7/2012
New York Presbyterian/Weill Cornell Center for Lymphoma and Myeloma
mi
from
New York, NY
Click here to add this to my saved trials
Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors
Neurotoxicity in Primary Central Nervous System Lymphoma: An International, Collaborative, Observational Study of Cognition in Long-Term Survivors
Status: Enrolling
Updated:  3/22/2012
Oregon Health and Science University
mi
from
Portland, OR
Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors
Neurotoxicity in Primary Central Nervous System Lymphoma: An International, Collaborative, Observational Study of Cognition in Long-Term Survivors
Status: Enrolling
Updated: 3/22/2012
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Sutter East Bay Hospitals
mi
from
Berkley, CA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Sutter East Bay Hospitals
mi
from
Berkley, CA
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Palm Springs Research Institute
mi
from
Hialeah, FL
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Palm Springs Research Institute
mi
from
Hialeah, FL
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
MCG Cancer Center
mi
from
Augusta, GA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
MCG Cancer Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Kansas University Medical Center
mi
from
Kansas City, KA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Kansas University Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
University of Kentucky Markey Cancer Center Clinical Research Organization
mi
from
Lexington, KY
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
University of Kentucky Markey Cancer Center Clinical Research Organization
mi
from
Lexington, KY
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Montefiore Medical Center
mi
from
Bronx, NY
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Mid Dakota Clinical P.C. - Cancer Treatment and Research Center
mi
from
Bismarck, ND
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Mid Dakota Clinical P.C. - Cancer Treatment and Research Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Gabrail Cancer Center
mi
from
Canton, OH
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Pharma Resource
mi
from
East Providence, RI
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Pharma Resource
mi
from
East Providence, RI
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Virginia Commonwealth University
mi
from
Richmond, VA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
Phase I Clinical Trial of Bendamustine, Lenalidomide and Rituximab in B-Cell Lymphoid Malignancies
Status: Enrolling
Updated:  4/3/2012
Georgetown University Hospital Lombardi Cancer Center
mi
from
Washington,
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
Phase I Clinical Trial of Bendamustine, Lenalidomide and Rituximab in B-Cell Lymphoid Malignancies
Status: Enrolling
Updated: 4/3/2012
Georgetown University Hospital Lombardi Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation
T-Regulatory Cell Kinetics Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation
Status: Enrolling
Updated:  4/10/2012
Texas Children's Hospital
mi
from
Houston, TX
Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation
T-Regulatory Cell Kinetics Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation
Status: Enrolling
Updated: 4/10/2012
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant
T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors
Status: Enrolling
Updated:  4/10/2012
Texas Children's Hospital
mi
from
Houston, TX
T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant
T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors
Status: Enrolling
Updated: 4/10/2012
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant
T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors
Status: Enrolling
Updated:  4/10/2012
Baylor College of Medicine
mi
from
Houston, TX
T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant
T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors
Status: Enrolling
Updated: 4/10/2012
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Tacrolimus and ATG as GVHD Prophylaxis in Patients Undergoing Related Donor HSCT
A Phase II Study of Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  4/30/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Tacrolimus and ATG as GVHD Prophylaxis in Patients Undergoing Related Donor HSCT
A Phase II Study of Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 4/30/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Open-Label Extension Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Status: Enrolling
Updated:  5/10/2012
Stanford University
mi
from
Stanford, CA
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Open-Label Extension Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Status: Enrolling
Updated: 5/10/2012
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Phase II Pilot Efficacy Trial of the Combination Regimen Oncaspar/Doxil/Decadron (ODD) in Patients With Refractory Lymphoid Malignancies
Status: Enrolling
Updated:  5/11/2012
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Phase II Pilot Efficacy Trial of the Combination Regimen Oncaspar/Doxil/Decadron (ODD) in Patients With Refractory Lymphoid Malignancies
Status: Enrolling
Updated: 5/11/2012
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss
Status: Archived
Updated:  5/11/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss
Status: Archived
Updated: 5/11/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and SLL
Status: Enrolling
Updated:  5/31/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and SLL
Status: Enrolling
Updated: 5/31/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma
A Pharmacodynamically-Guided Dose Escalation Phase I Study to Assess the Safety of AFM13 (Recombinant Antibody Construct Against Human CD30 and CD16A) in Patients With Refractory and/or Relapsed Hodgkin Lymphoma
Status: Enrolling
Updated:  6/15/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma
A Pharmacodynamically-Guided Dose Escalation Phase I Study to Assess the Safety of AFM13 (Recombinant Antibody Construct Against Human CD30 and CD16A) in Patients With Refractory and/or Relapsed Hodgkin Lymphoma
Status: Enrolling
Updated: 6/15/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Status: Enrolling
Updated:  6/22/2012
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Status: Enrolling
Updated: 6/22/2012
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Status: Enrolling
Updated:  6/22/2012
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Status: Enrolling
Updated: 6/22/2012
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas
Status: Enrolling
Updated:  6/28/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas
Status: Enrolling
Updated: 6/28/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas
Status: Enrolling
Updated:  6/28/2012
Baylor College of Medicine
mi
from
Houston, TX
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas
Status: Enrolling
Updated: 6/28/2012
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
Status: Enrolling
Updated:  7/16/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
Status: Enrolling
Updated: 7/16/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma
A Phase I/II Study of Intravenous AMD3100 Added to a Mobilization Regimen of G-CSF to Increase the Number of Autologous Peripheral Blood Stem Cells Collected From Patients With Lymphoma
Status: Enrolling
Updated:  7/19/2012
Washington University
mi
from
St. Louis, MO
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma
A Phase I/II Study of Intravenous AMD3100 Added to a Mobilization Regimen of G-CSF to Increase the Number of Autologous Peripheral Blood Stem Cells Collected From Patients With Lymphoma
Status: Enrolling
Updated: 7/19/2012
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma
Biaxin(Clarithromycin)Based Antibiotic Therapy In Previously Untreated, Advanced Stage Indolent Lymphoma
Status: Enrolling
Updated:  7/25/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma
Biaxin(Clarithromycin)Based Antibiotic Therapy In Previously Untreated, Advanced Stage Indolent Lymphoma
Status: Enrolling
Updated: 7/25/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies or Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/26/2012
Virginia G. Piper Cancer Center
mi
from
Scottsdale, AZ
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies or Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/26/2012
Virginia G. Piper Cancer Center
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies or Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  7/26/2012
Esanex Investigational Site
mi
from
Nashville, TN
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies or Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 7/26/2012
Esanex Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  7/30/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 7/30/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Lymphoma Follow-up
Lymphoma Follow-up Protocol
Status: Enrolling
Updated:  8/2/2012
NIA Clinical Research Unit
mi
from
Baltimore, MD
Lymphoma Follow-up
Lymphoma Follow-up Protocol
Status: Enrolling
Updated: 8/2/2012
NIA Clinical Research Unit
mi
from
Baltimore, MD
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
Stanford Univ Med Ctr
mi
from
Stanford, CA
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
Northwestern University Dept of Dermatology
mi
from
Chicago, IL
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
Northwestern University Dept of Dermatology
mi
from
Chicago, IL
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
Columbia University, Dept of Dermatology
mi
from
New York, NY
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
Columbia University, Dept of Dermatology
mi
from
New York, NY
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
NYU Medical Center Dept. of Dermatology
mi
from
New York, NY
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
NYU Medical Center Dept. of Dermatology
mi
from
New York, NY
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
Duke Univ Med Ctr
mi
from
Durham, NC
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
Oklahoma University
mi
from
Tulsa, OK
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
Oklahoma University
mi
from
Tulsa, OK
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
Fox Chase Cancer Center
mi
from
Philadelphia, PA
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated:  8/7/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response
Status: Enrolling
Updated: 8/7/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials